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Editorial
Primary aldosteronism (PA) is characterized by hypertension 
caused by inappropriately high adrenal aldosterone secretion, con-
secutively low plasma renin, and an elevated aldosterone to renin 
ratio. It is nowadays the universally accepted main cause of endo-
crine hypertension. According to the most recent epidemiological 
data, PA is present in 5.8 % of unselected hypertensives in primary 
care, 6–12 % of hypertensives treated in hypertension centers, and 
up to 30 % in subjects with resistant hypertension [1]. Despite this 
high prevalence, a recent survey demonstrated that screening for 
PA is not universally followed. Renin and aldosterone measure-
ments, the basis for PA screening, are currently performed by only 
7 % of general practitioners in Italy and 8 % in Germany [2]. Accord-
ingly, the prevalence of PA was low with 1 % among hypertensives 
in Italy and 2 % in Germany. In a retrospective cohort study of 4660 
patients with resistant hypertension in California the screening rate 
for PA was 2.1 % [3]. Based on these data, it is clear that we still miss 
the majority of PA cases, despite advances in diagnosis and therapy.
Early diagnosis of PA would definitely save many lives: morbid-
ity of PA subjects compared with matched hypertensives is sub-
stantially increased at the time of diagnosis [4]. Despite this unfa-
vorable baseline situation, the long-term prognosis is excellent with 
specific treatment measures, unilateral adrenalectomy for a unilat-
eral adenoma, and mineralocorticoid antagonist treatment for bi-
lateral adrenal hyperplasia. In a recent meta-analysis, long-term 
mortality of patients with PA, independent of subtype, decreased 
progressively at year 5 and 7 below the level of primary hyperten-
sion, an effect even more pronounced in unilateral PA following 
unilateral adrenalectomy [5].
It has become a tradition for clinicians and researchers to meet 
every second year in Munich at a conference called “Progress in Pri-
mary Aldosteronism”. From October 13 to October 15, 2019 we 
held the 6th conference at the Carl Friedrich von Siemens Stiftung 
and celebrated the 10th anniversary with a focus on “New Players 
on the Block”. The primary focus of the meeting remained: to ad-
vance the knowledge of PA and to discuss new concepts of diagno-
sis and treatment. However, at this anniversary the organizers also 
concentrated on topics and speakers who had not been present in 
the past. Owing to the special genius loci of the Carl Friedrich von 
Siemens Foundation at the Nymphenburg castle, and the enthusi-
asm of more than 100 attending scientists from Europe and over-
seas, the meeting gave another excellent example of a successful, 
international, medium-sized disease-oriented symposium.
With the generous support of the Deutsche Forschungsgemein-
schaft and the Carl Friedrich von Siemens Stiftung we were able to in-
vite most of the internationally renowned primary aldosteronism 
experts. The present volume of Hormone and Metabolic Research is 
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entirely dedicated to reviews based on PIPA-6 presentations and 
gives an excellent overview over the current status of the field.
The manuscripts are organized according to their relation to the 
diagnostic and therapeutic challenges of PA. The study of Gruber 
and Beuschlein [6] analyses the relevance of hypokalemia as a lead 
symptom for PA. An important clinical manifestation of PA is atrial 
fibrillation, as outlined by the study of Pan et al. [7]. A conundrum 
has been the association between PA and obstructive sleep apnea 
syndrome, which has recently received quite some attention and 
is covered in this issue by Pecori et al. [8]. Wannachalee and Turcu 
[9] review the diagnostic value and pathophysiologic implications 
of steroid profiles determined by liquid chromatography mass spec-
trometry, an area which has attracted substantial attention in re-
cent years. Similarly, agonistic angiotensin II type 1 receptor anti-
bodies have become a hot topic in aldosterone research and will be 
covered by the review article of Meyer et al. [10]. A neglected area 
of PA research is the regulation of sodium chloride in states of nor-
mal and excess aldosterone secretion, as covered by the article by 
Adolf et al. [11]. Tömböl et al. reviews the evidence for micro RNA 
as novel markers in the diagnostic work-up of PA [12]. In an origi-
nal publication, Handgriff et al. analyze the association between 
glucocorticoid co-secretion, assessed by the 1 mg dexamethasone 
suppression test, on the prevalence and the time course of thyroid 
antibodies in PA [13]. In a series of pathophysiologic manuscripts, 
the role of mast cells [14], expression of aldosterone synthase in 
adrenalectomy samples [15], the role of aldosterone producing cell 
clusters [16], and the methodologic advances obtained by tissue 
mass spectrometry imaging [17] are analyzed. Finally, the study of 
Gao et al. [18] gives a comprehensive overview on calcium metab-
olism in PA, followed by an in-depth study on clinical determinants 
of surgical success by Naruse et al. [19]. The final word and outlook 
has the nestor of primary aldosteronism research, John Funder, in 
his commentary “Primary Aldosteronism: Where Are We Now? 
Where to from Here” [20].
This special issue of Hormone and Metabolic Research gives the 
interested reader the opportunity to understand where we are, and 
where our research has to go until the next PIPA meeting. We would 
like to thank all authors for their valuable contributions to this Spe-
cial Issue.
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